ENSC vs. LEXX, OCX, OKYO, OMGA, SLGL, RNXT, PMN, AKTX, IXHL, and LSTA
Should you be buying Ensysce Biosciences stock or one of its competitors? The main competitors of Ensysce Biosciences include Lexaria Bioscience (LEXX), OncoCyte (OCX), OKYO Pharma (OKYO), Omega Therapeutics (OMGA), Sol-Gel Technologies (SLGL), RenovoRx (RNXT), ProMIS Neurosciences (PMN), Akari Therapeutics (AKTX), Incannex Healthcare (IXHL), and Lisata Therapeutics (LSTA). These companies are all part of the "pharmaceutical products" industry.
Ensysce Biosciences vs.
Lexaria Bioscience (NASDAQ:LEXX) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, community ranking, institutional ownership, earnings, analyst recommendations, valuation and dividends.
Lexaria Bioscience currently has a consensus price target of $11.00, indicating a potential upside of 471.73%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, equities analysts plainly believe Lexaria Bioscience is more favorable than Ensysce Biosciences.
Lexaria Bioscience has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Ensysce Biosciences has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500.
Lexaria Bioscience has higher earnings, but lower revenue than Ensysce Biosciences. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.
Lexaria Bioscience received 3 more outperform votes than Ensysce Biosciences when rated by MarketBeat users. Likewise, 100.00% of users gave Lexaria Bioscience an outperform vote while only 60.00% of users gave Ensysce Biosciences an outperform vote.
Ensysce Biosciences has a net margin of -179.26% compared to Lexaria Bioscience's net margin of -1,473.04%. Lexaria Bioscience's return on equity of -88.88% beat Ensysce Biosciences' return on equity.
13.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are held by institutional investors. 26.4% of Lexaria Bioscience shares are held by insiders. Comparatively, 7.9% of Ensysce Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Lexaria Bioscience's average media sentiment score of 0.00 equaled Ensysce Biosciences'average media sentiment score.
Summary
Lexaria Bioscience beats Ensysce Biosciences on 13 of the 16 factors compared between the two stocks.
Get Ensysce Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENSC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ensysce Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:ENSC) was last updated on 1/21/2025 by MarketBeat.com Staff
